Forgot Password?
Return to Course Listing

CME: Migraine Updates from the American Headache Society Annual Meeting (AHS 2020)

Activity Description / Statement of Need:

In this online CME self-learning program:

Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. It is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. The condition has been identified as one of the most common neurological disorders, and in the United States, its prevalence in the general population is approximately 12%. In children, the prevalence ranges from 1% to 4% and does not present more commonly in either sex. However, after menarche, its prevalence in females (18%) is approximately three times higher than in males.

Moreover, professional guidelines relating to the classification, diagnosis, prophylaxis, and treatment of migraine headaches have been updated recently, and communicating related information to healthcare professionals in a timely manner is a demonstrated need. The literature suggests that practicing healthcare professionals are often times unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming. Generalists may be at particular risk for missing updates in standards relating to migraine subtypes like menstual and abdominal migraines.

Target Audience:

Neurologists and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with migraine.

This program is supported by an educational grant from Amgen.

This activity is free of charge.

Release Date: August 08, 2020 -- Expiration Date: August 08, 2022

Faculty: Stewart Tepper, MD


Generally an annual scientific meeting is a buffet of new information and trial presentations, lectures on the cutting edge of the scientific developments in the therapeutic field, industry supplied information, and networking. The AHS Virtual Annual Scientific Meeting was a necessarily shortened set of lectures, platform presentations, and abstracts, all reduced in lecture time due to the web-based format, and those finally selected were of the top quality. Still, the meeting remained a smorgasbord, from which to select the most interesting and useful material:

  • COVID-19 headache
  • Basic science discoveries
  • Epidemiology and outcome studies
  • New information on recently approved therapies, acute and preventive
  • New information on therapies in development
  • Clinical reports on experience with treatments

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the pathophysiology and clinical presentation of headache in patients with COVID-19.
  • Describe migraine basic science, epidemiology, outcomes, and therapy findings presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting of 2020.
  • Categorize new therapies and those in development based on data presented.
  • Synthesize overall presentation material from the AHS CME meeting for further clinical application.


ACCME Activity #201540535

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians: For applicable courses, to attain maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: Not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in the "Accreditation" section on this page, then it does NOT provide MOC credit.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-20-039-H01-P. ACPE Accreditation effective 08/08/2020, expires 08/08/2022. This is a Application (A)-type activity.


Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Stewart J. Tepper, MD, Director, Dartmouth Headache Center, Professor of Neurology, Geisel School of Medicine at Dartmouth, discloses that he has received financial compensation from consulting, ownership interest and/or advisory board work from: Acorda, Aeon, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, CRG, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK. Guidepoint Global, Healthcare Consultancy Group, Health Sciences Communications, Impel, Lundbeck, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Mocira, Nordic BioTech, Novartis, Pulmatrix, Percept, Reckner Healthcare, Relevale, Revance, SAI Medical Partners, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Trinity Partners, XOC, and Zosano.

Disclosures of Educational Planners: Charles Turck, PharmD, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Amgen.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies

Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care

Coronavirus disease 2019 (COVID-19) preparedness, facts, and management